Stock Analysis
- United States
- /
- Medical Equipment
- /
- NasdaqGM:HYPR
US Penny Stocks To Consider In February 2025
Reviewed by Simply Wall St
As January 2025 comes to a close, the United States stock market has seen its share of ups and downs, with major indexes posting gains despite recent tariff announcements. For investors looking beyond the well-known giants, penny stocks—often representing smaller or newer companies—can offer intriguing possibilities. Although the term "penny stocks" may seem outdated, these investments remain relevant today as they can provide unique opportunities for growth and value that larger firms might overlook.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.89 | $6.46M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $121.65M | ★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.2827 | $10.4M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.94 | $89.18M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
BTCS (NasdaqCM:BTCS) | $3.05 | $52.92M | ★★★★★★ |
North European Oil Royalty Trust (NYSE:NRT) | $4.52 | $41.54M | ★★★★★★ |
Permianville Royalty Trust (NYSE:PVL) | $1.46 | $48.18M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $1.27 | $22.53M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.9463 | $85.11M | ★★★★★☆ |
Click here to see the full list of 709 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
LiveOne (NasdaqCM:LVO)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: LiveOne, Inc. is a digital media company focused on acquiring, distributing, and monetizing live music, Internet radio, podcasting/vodcasting, and music-related streaming and video content with a market cap of $138.72 million.
Operations: The company generates revenue through its Media segment ($7.63 million), Slacker service ($72.73 million), and PodcastOne platform ($47.46 million).
Market Cap: $138.72M
LiveOne, Inc. faces challenges typical of penny stocks, such as high volatility and unprofitability, though it has reduced its debt to equity ratio significantly over five years. Despite a stable cash runway exceeding three years due to positive free cash flow, the company remains unprofitable with earnings forecasted to decline by 3.3% annually over the next three years. Recent Nasdaq notifications highlight compliance issues with listing rules due to low share prices, while strategic alternatives are being explored for shareholder value enhancement. LiveOne's revenue sources include its Slacker service and PodcastOne platform generating substantial income relative to its market cap of US$138.72 million.
- Take a closer look at LiveOne's potential here in our financial health report.
- Assess LiveOne's future earnings estimates with our detailed growth reports.
Hyperfine (NasdaqGM:HYPR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Hyperfine, Inc. is a medical device company that offers MRI products across the United States, Europe, and Middle Eastern markets, with a market cap of $80.24 million.
Operations: The company generates revenue from its Medical Imaging Systems segment, totaling $13.26 million.
Market Cap: $80.24M
Hyperfine, Inc. presents a mixed investment case typical of penny stocks. The company is unprofitable with a negative return on equity of -70.32% and has seen its losses increase by 7.4% annually over the past five years, with no profitability expected in the near term. However, it maintains a strong cash position with short-term assets of US$64.1 million covering both short and long-term liabilities comfortably and remains debt-free. Recent strategic expansions into Turkey, Israel, and Saudi Arabia enhance its global reach for the Swoop® system, supported by CE approval for advanced software in Europe—potentially driving future revenue growth beyond its current US$13.26 million from medical imaging systems.
- Jump into the full analysis health report here for a deeper understanding of Hyperfine.
- Explore Hyperfine's analyst forecasts in our growth report.
Kaltura (NasdaqGS:KLTR)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Kaltura, Inc. offers a range of software-as-a-service (SaaS) and platform-as-a-service (PaaS) solutions globally, with a market cap of approximately $377.23 million.
Operations: The company's revenue is derived from two primary segments: Media & Telecom, contributing $50.27 million, and Enterprise, Education and Technology, which accounts for $127.32 million.
Market Cap: $377.23M
Kaltura, Inc. reflects the dual nature of penny stocks with both opportunities and challenges. The company remains unprofitable but has successfully reduced its losses over the past five years by 7.9% annually, indicating gradual financial improvement. Its short-term assets of US$118.5 million exceed both short and long-term liabilities, showcasing a solid liquidity position without significant shareholder dilution recently. Despite a negative return on equity of -152.34%, Kaltura's cash runway extends beyond three years due to positive free cash flow trends. Recent buyback activity and stable revenue growth suggest cautious optimism amid inherent volatility in its share price movements.
- Click here to discover the nuances of Kaltura with our detailed analytical financial health report.
- Learn about Kaltura's future growth trajectory here.
Make It Happen
- Access the full spectrum of 709 US Penny Stocks by clicking on this link.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Jump on the AI train with fast growing tech companies forging a new era of innovation.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Hyperfine might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:HYPR
Hyperfine
A medical device company, provides magnetic resonance imaging (MRI) products in the United States, Europe, and Middle Eastern Markets.